REFERENCES

1) Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality Neurology 1967;17:427-442

2) Rajput AH, Offord KP, BeardCM, Kurland LT. Epidemiology ofparkinsonism: Incidence, clasification and mortality. And  Neurol 1984; 16:278-282.

3)Forno LS. Pathology of Parkinson´s   disease: The importance of the substantia nigra and lewy bodies. In: Stern GM(ed), Parkinson's diesease. Baltimore: Johns Hopkins Press,1990:1985-238.

4)Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 1986: 45:1-18.

5) Morgante L, Rocca WA, Di Rosa AE. et al. Prevalence of Parkinson's disease and other types ofparkinsonism: A door-to-door survey ¡n three sicilian municipalities. Neurology 1992;  42:1901-1907.

6) Langston JW. Current theories on the cause of Parkinson's disease. J Neurol Neurosurg Psychiatry (Special Suppl) 1989:13-17.

7) Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust W,I. Cortical  glucose metobolism in Parkinson's diseasewithout dementia. Neurobiol Aging 1994; 15(3): 329-35.

8) Kondo K, Kurland LT, schull W.J. Parkinson's dis ase. Genetic analysis andevidence of a multifactorial etiology. Mayo Clin Procced 1973: 48: 465-475.

9) Uitti R.J Clane DB. Parhogenesis of idiopathic paikinsonism. Eur neurol 1993; 33(Suppl,1): 6-23.

10) Olanow CW. Oxidation reactions in Parkinson´s  discase. Neurology 1990; 40 (Suppl.3): 32-37.

11) Poirier J, Thiffilult Ch. Al e radicals involeed ¡ir the palhogonesis of idiopathic Parkiii.son's disease?. Erir Neurol 1993~33(suppl.1): 38-43.

12) Dirnagl U. Cerebral ischemia: The microcirculation as trigger and target. Prog Brain Res 1993, 96: 49-65

13) K, Matsumoto M, Oda T, et al. Free radical generattion during brief period of cerebral ¡schemia may trigger delayed neuronal death. Neurociences 1990: 35:551-,558.

14) Rafael H, Ayulo V. Consideraciones sobre la etiología de la enfemedad de Parkinson. Mundo Médico Mex 1990; 17  (197):11-17.

15) Rafael H. Deterioro de la microcirculación en la sustancia negra como causa de la enfermedad   de Parkinson. Rev Med IPPS (Perú) 199SA(2):51-56.

16) Croshy EC, Humphrey T, Lauer EW, Correlative antomy of the nervous system  New York: The MacMillan Co 1962:686-688.

17) Fallon J111, Lougghlin SE. Substantia nigra. ln:Paxinos G(ed). The rat nervous system.  Vol 2. Sydney:Academic Press, INC 1985: 353-374.

18) G¡bb WRG, Les AJ. Anatomy. pigmentation, ventral and dorsal subpopuations  of the substantia  nigra, and differential cell death ¡n Parkinson's disease. J Neurol Neurosurg Psychiatry 1991:54:388-396.

19) McGeer 0L, McGeer EG, Suzuki JS. Aging and extrapyramidal functioon. Arch Neurol 1997;34:33-35 . 

20) German DC, Schlusselberg DS, Woodward DJ. Three dimensional computer reconstruction of midbrain dopaminergic neuronal population: From mouse to man. J Neurol 1983:57:243-254.

21) Szabo J. Organization of the ascending striatal afferents in monkey. J comp Neurol 1980:189:307-321.

22) Hornykiewics 0, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986; 45:19-34.

23) Carpenter MB. Anatomical Organization of the corpus atriatum and related nuclei.Res Publ Assoc Res Nerv Ment Dis 1976; 55:1-36,

24) Braak H, Braak E. Nuclear configuration and neuronal types of yhe nucleus niher in the brain of human adult. Hum Neurobiol 1986:5:71-82.

25) Cruz-Sancbez FF, Path MRC, Cardozo A, Tolosa E. Neuronal changes in the substantia nigra with aging:A Golgi study, J Neuropathol Exp Neurol 1995;54:74-81.

26) Dalhlstrorn A, Fuxe K. Evidence for the existence of monoaminecontaining neurons in the central nervous system, Acta Physiol Scand 1964;62(Suppl.232):1-55.

27) Ungerstedt V. Stejeotaxic mapping of the monoamine pathway in the rat brain. Acta Physiol Scand 1971:82 (Suppl. 367):1-48.

28) German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: Computet visualization. Ann Neurol 1989; 26:507-514.

29) Finley KH. Angio-archirecture of the substantia nigra and its pathogenic significance. Arch Neurol Psychiat (Chic) 1936:36:118-127.

30) Percheron G. Les artéres du thalamus humanus, ll: Artéres et territoires thalamiques paramédians de I´artére basilaire cornmunicante Rev Neurol (Paris) 1976; 132(5):309-324.

31) Sieben G, De Reuck J, Vander Eecken H. Thrombosis of the mesencephalic artery, A Clinico-pathological study of two cases and its correlation with the arterial vascularization. Acta Neurol Belg 1977:77:151-162.

32) Zeal AA, Rhoton AL. Microsurgical anatomy of the posterior cerebral artery. J Neurosurg 1978;48:534-593

33) Pedroza A, Dujovny M, Ausman JI, et al. Microvascular anatomy of the interpencular fossa. J Neurosurg 1986;64:484-493.

34) Riggs HE, Rupp C. Variation inforin of the circle ot willis. The relation of the variations to collateral circulation Anatomic analysis. Arch Neurol 1963:8:24-30.

35) Saeki N, Rhoton AL. Microsurgical anatomy of the upper basilar artery and the posterior circle of Willis. J Neurosurg 1977:46:563-578.

36) Rafael H. Nervios Craneanos. Segunda Edición. Capitulo 3. México DF:Editorial Prado 1995:49-66.

37) Caplan LR. Intracranial branch atheroinatous disease: A neglected, understudied, and underused concept. Neurology 1989; 39:1246-1250.

38) Kalaria RN. Brain inicrovascuiar in aging, Neurobiol Aging 1994;15(6): 765-766.

39) Stopford Jsb. The arteries of the pons and medulla oblongata. J Anat 1916:50:13 1-164.

40) Rafael H, Chimal MC. El tronco basilar y la arteria  vertebral intracraneal. Estudio anatómico postmorten. Neurol Neuroc Psiq Méx 1983; 24:105-110.

41) Stenevi  U, Bjorklund A, Svendgaard NA. Tiansplantation of central and peripheral monoamine neurons to the adult rat brain: Technique and conditions for survival. Brain Res 1976: 114:1-20.

42) Lassen NA, Ingvar DH, Skinhoj E, Brain function and blood flow. Sci Am  1978, 239(4): 62-71. 

43) Rafael H. Tejidos donadores de catecolaininas. Una revisión. Diagnóstico (Perú) 1995;34:42-49.

44) Issidorides Mr. Neuronal vascular relationships in the zona compacta of normal and parkinsonian substantia nigra. Brain Res 1971:25:289-299.

45) Felten DI, Crutcher KA. Neuronal-vascular relationships in the raphe nuclei. locus coeruleus and substantia nigra in primates. Am J Anat 1979:155:467-472.

46) Scheibel AB, Tomiyasu U.A dendrite-vascular relationship in the substantia nigra. Exp Neurol 1980:70:717-720.

47) Finley KH, Cobb S. The capillary bed of the locus coeruleus. J Comp Neurol 1940;73:49-58.

48) Scharrer E, Gaupp R. Neuere befunde am nucleus supraopticus und nucleus paraventricularis des menchen. Z Neurol 1933; 148: 766- 772.

49) Axelrod J, Kopin 1j. ne uptake, flease mid metabolism of noradrenaline in sympathetic nerves. Prog Brain Res 1969;31:21-32,

50) Kirshner N. Biosylithesis of the catecholamines. In: Greep RO and Astwood EB(eds). Handbook of physiology. Section 7: Endocrinology. Volume VI: Adrenal Gland. Washington DC: Am physiol Soc 1975:341-355.

51) Rafael H. El epiplón:Transplante al sistema nervioso. Capítulo 10. México DF:Editorial Prado 1996:101-123.

52) Rinne UK, Sonninen V, Riekkimen P, Laaksame H. Postmortem findings in parkinsonian patients treats with L-Dopa: Biochemical consideration. In:Yahr(ed). Current concepts in the treatmen of parkinsonism. New York:Raven Press 1974:211-233.

53) Farley IJ, Hornykiewics O. Noradrenaline distribution in subcortical areas of the human brain. Brain res 1977;126:53-62.

54) Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T. L-threo-3,4 dihydroxylserine treatment for akinesia and freezing of parkinsonism. Proc Japan Acad 1981;57:351-354.

55) Richardson DE, Heath RG. Treatment of Parkinson's disease by injection of noradrenaline into the corpus striatum. Acta Neurochir (Wien) 1992;117:124.

56) Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. TINS 1990;13(7):244-258.

57) McGeer EG, MCGeer Pl, Wada JA. Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 1971;18:1674-1658.

58) Lloyd Kg, Hornykiewicz O. Occurrence and distribution of aromatic Laminoacid (L-Dopa) decarboxylase in the human brain. J Neurochem 1972;19:1549-1559.

59) Kopin IJ, Silberstein SD. Axons of sympathetic neurons:Transport of anzymes in vitro and properties of axonal sprouts in vitro. Pharmacol Rev 1972;24:245-254.

60) Loomis TC, Yees G, Stahl WL. Regional and subcellular distribution of superoxide dismutase in brain. Experimenti 1976;32:1374-1376.

61) Kish Sj, Morito C, Hornykiewiez 0. Glutathione peroxidase activity in Parkinson's disease brain, ENeurosci Lett 1985:58:343-346.

62) Hassler R. Zur Pathologie der paralysis agitans und des postenzephalitischen parkinsonisnius. J Psychol Neurol (Lpz) 1938; 48:387-476.

63) Greenfield JD. Systern degenerationnis in the cerebellum. brain steE and spinal cord. In:Blackwood W. et at (eds). Greenfield´s Neurophatology. London:Edward Arnold 1963:581-601.

64) Zweig RM, Cardillo JE, Cohen phD, Giere S, Hedreen JC. The locus, ceruleus and dementia in Parkinson's disease. Neurology 1993;43:986-991 

65) Gai WP, Vickers JC, Blurnbergs, Blessing WW, Loss of non-phosphorylated neurofilament inmunoreactivity, with presentation of tyrosine hydroxylase. in surviving substantia nigra neurons in Parkinson's  disease. J Neurol Neurosurg Psychiatry 1994:57:1039-1046.

66) Ambani LM, VanWoert MH, Murphy S. Brain peroxidase and catalase  in Parkinson's disease. Arch Neurol 1975;32:114-118.

67) Sggu H, Cooksuy J, Dexter D, et al. A selective increase in particulate Superoxide dismutase activity in Parkinsonian substantia nigra J. Neurochem 1989; 53:692-697.

68) Wolff SP, Garner A, Dean RT. Free radicals, lipids and protein degradation. Trends Biol Sci 1986:11:27-31.

69) De la Torre JC. Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci Biobehav Res 1994:18:397-401.

70) Raichle ME, Grubb RL, Gado MH, Eichling SO, Ter-Pogossian MM, Correlation between regional cerebral blood flow and oxidative metabolism: In vivo studies in man. Arch Neurol 1976:33:523-526.

71) Gaetani P, Lombardi D. Brain damage following subarachnoid hemorrhage: The imbalance between anti-oxidant system and lipid peroxidative processes. J Neurosurg Sci 1992;36:1-10.

72) Jenner P, Dexter D, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy bodies disease. Ann Neurol 1992:32 :S₈₂-S₈₇

73) Moonen G, Rogister B, Leprince P. et al Neurono-glial interaction and neural plasticity. Prog Brain Res 1990;86:63-73.

74) Bradshaw RA, Altin JG, Blader M, et al. Neurotrophic factors in the CNS: Biosynthetic processing and functional response. Prog Brain Res 1990;86:157 167

75) Frederickson RCA. Astroglia in Alzheimer's disease. Neurobiol Aging 1992; 13(2):239-252.

76) Kimelberg HK, Norenberg MD. Astrocytes. Sci Am 1989; 260:44-52.

77) Escourolle R, de Recowdo J, Gray F. Etude anatomo-pathologique des syndromes parkinsoniens. In: Juriagurry JA and Gauthier G(eds), Monoamines et noyaux gris centraux et syndrome de Parkinson. Paris:Masson et Cie 1971:173-229.

78) Goldsmith HS(ed). The omentum: Research and clinical applications. New York: Springer-Verlag 1990:1-252.

Regresar